Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Chemiphar Considers Establishing Manufacturing Base in Vietnam
July 16, 2013
- Otsuka Forms Clinical Research Firm in UK as Europe’s R&D Hub
July 12, 2013
- Cancer, CNS Diseases to Be Important Fields for MSD Over Next 10 Years: Pres. Alvarez
July 12, 2013
- Anti-HIV Treatment Prezista Naive Tablet 800 mg Approved: Janssen
July 12, 2013
- Daiichi Sankyo Voluntarily Recalls Mevalotin Granules 1% Due to Contamination with Vitamin Capsule
July 12, 2013
- Empagliflozin Alone Lowers Blood Glucose Level: BI, Eli Lilly
July 11, 2013
- Sanofi Begins Domestic PII Study of Vaccine Against CDIs
July 11, 2013
- Mediceo’s New Tokyo Logistics Center Completed, Operations to Start in September
July 11, 2013
- Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
- Sumitomo Bakelite Files Application for Gene Chip for Cancer Diagnosis
July 11, 2013
- Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
- PTH Preparations, New Drugs Grow in Intense Anti-Osteoporosis Drug Competition
July 10, 2013
- Kyowa Kirin Aims to Lead the Domestic Parkinson’s Disease Market in 5 Years on the Strength of Nouriast and 3 Other Products
July 10, 2013
- Will the ARB Market Regain Steam in FY2013? Leading ARB Drug Marketers Forecast Double-digit Growth in FY2013
July 10, 2013
- High Price, Concerns About Safety Could Pose Hurdle to Success of Pfizer Japan’s Xeljanz
July 10, 2013
- Kyowa Kirin Steps into Diabetes Market with 7th DPP-4 Inhibitor Onglyza
July 9, 2013
- CMIC Subsidiary SSI to Set Up Committee to Investigate Suspected Clinical Data Manipulation
July 9, 2013
- Ethical Drug Sales Up 3.3% in May: Crecon Report
July 9, 2013
- Kyorin to Merge 2 Domestic Development Sites in Tochigi Prefecture
July 8, 2013
- Daiichi Sankyo to Promote Osteoporosis Treatment Pralia with Focus on Appropriate Use
July 5, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…